Joshua J. Neumiller, PharmD, CDCES, of the American Diabetes Association discusses pharmacists’ role in diabetes and CKD care from ASN Kidney Week 2026
|Videos|March 25, 2013
Acute Coronary Syndromes Lecture
A lecture on acute coronary syndromes by Kim A. Eagle, MD, director of the Cardiovascular Center at the University of Michigan Health System.
Advertisement
In this video, Kim A. Eagle, MD, Albion Walter Hewlett Professor of Internal Medicine and director of the Cardiovascular Center at the University of Michigan Health System, lectures on acute coronary syndromes.
Advertisement
Related to this article
Jai Radhakrishnan, MD, MBBS, MS, FASN, discusses why IgG4-related kidney disease is often missed and what the MITIGATE subgroup data presented at ASN Kidney Week 2026 show.
From AKI dosing to CKM therapeutic inertia, experts at ASN Kidney Week 2026 pointed to pharmacists as key to moving new kidney data into practice.
Kidney Week 2026 posters show low-density lipoprotein cholesterol (LDL-C) fell by half in patients receiving dialysis, and oral enlicitide needed no dose adjustment for renal impairment.
Walgreens adds virtual coverage navigation, Medicare GLP-1 Bridge support, and pharmacist follow-up calls as GLP-1 discontinuation remains high.
A helpful guide for pharmacists if teas, supplements, or cultural foods are part of a patient's regular routine.
Real-world data from ASN Kidney Week show GLP-1 RA users with CKD and obesity had lower rates of kidney failure, death, and heart failure exacerbation.
Hiddo J. L. Heerspink, PharmD, PhD, discusses SOLSTICE elecoglipron data, finerenone in FSGS, and glucagon’s kidney effects from ASN Kidney Week 2026.
Advertisement
Advertisement
Trending on Pharmacy Times
1
PCSK9 Inhibition Lowers LDL-C in Patients With Kidney Disease
2
The Growing Role the Specialty Pharmacy Team Plays in Helping Breast Cancer Patients Navigate Treatment
3
GLP-1 RAs Tied to Lower Kidney Failure Risk in Patients With Obesity, CKD
4
Kidney Week 2026: Pharmacists' Growing Role in Kidney Care
5